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Abstract
There is much evidence to demonstrate that the presence of the metabolic syndrome 
(MetS) is associated with an increase in the incidence of pre-Alzheimer’s disease. The 
possible underlying mechanisms linking pre-Alzheimer’s disease and MetS are still 
unclear. This study summarizes and discusses the potential mechanisms involved in 
pre-Alzheimer’s disease under MetS conditions, including an increased brain oxidative 
stress, brain inflammation, brain mitochondrial dysfunction, hyper-phosphorylated tau 
protein, and amyloid beta production. This report focuses on brain mitochondrial altera-
tions in cases of pre-Alzheimer’s disease where MetS is also extant. The data from in vitro, 
in vivo, and clinical studies are included. In addition, potential interventions against pre-
Alzheimer’s disease in conjunction with MetS are summarized and discussed.
Keywords: mitochondria, brain, cognitive impairment, obesity, oxidative stress, 
inflammation
1. Introduction
1.1. Metabolic syndrome, pre-Alzheimer’s disease, and brain mitochondria
According to the consensus statement of the International Diabetes Federation, metabolic syn-
drome (MetS) is defined as abdominal obesity plus any two of four factors including raised 
triglycerides, reduced high-density lipoprotein (HDL) cholesterol, raised blood pressure, and 
elevated fasting plasma glucose [1]. The risk factors of MetS include genetic factors, physical 
inactivity, and too high a calorie intake or poor diet [2, 3]. It has been postulated that insulin 
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resistance is the main contributor toward MetS. Insulin resistance is a pathological condition, 
in which target tissues cannot take up glucose into the cells at the physiological insulin level. 
It is characterized by hyperinsulinemia with euglycemia. MetS is often represented by an 
obese-insulin-resistant condition. It can lead to the development of not only cardiovascular 
diseases but also stroke [4] and neurodegeneration [5]. In addition, data from clinical trials 
have indicated that hyperinsulinemia during insulin resistance is related to cognitive decline 
in elderly adults [6, 7]. MetS has been induced in several animal models to enable the inves-
tigation of the mechanisms responsible for the adverse effects of the MetS condition on cog-
nitive impairment. MetS has been induced in animal models by using high-fat/high-calorie 
diet consumption. Interestingly, previous studies have investigated the effects of long-term 
high-fat diet (HFD) consumption on metabolic and brain dysfunction [8, 9]. Those data dem-
onstrated that the consumption of a HFD for 8 weeks caused obese-insulin resistance or MetS, 
as indicated by central obesity, hyperinsulinemia, dyslipidemia, and raised blood pressure 
[8, 9]; however, cognitive impairment and brain insulin resistance were observed later at the 
end of 12 weeks of HFD consumption [8, 10]. Those findings suggest that the metabolic dis-
turbance preceded cognitive dysfunction in induced MetS
Pre-Alzheimer’s disease or mild cognitive impairment (MCI) is a condition of memory decline 
but does not significantly affect the normal function of a person’s life [11]; however, Alzheimer’s 
disease (AD) is an irreversible chronic neurodegenerative disease and it is the most common 
type of dementia [12]. The presence of neurofibrillary tangles and amyloid beta deposition 
in the brain is hallmarks of AD [12]. Recent studies have shown that the incidence of AD has 
increased in MetS subjects [13–15]. Those findings suggest that there is a possible connection 
in the pathogenesis between MetS and AD. Data from a clinical study suggest that oxidative 
stress is a key component that regulates the development of AD in MetS subjects [15]
Mitochondria are known as the major source of oxidative stress [16]. Brain mitochondrial 
dysfunction was observed in several pathological conditions, including MetS and AD [17–22]. 
That dysfunction causes increased oxidative stress [10] and leads to the activation of several 
stress kinases [19]. Subsequently, a raised oxidative stress impaired brain insulin receptor 
function [23], inhibited insulin-degrading enzymes and increased beta-secretase activity [23, 
24], resulting in increased hyperphosphorylated tau and amyloid beta deposition in the brain 
[19]. Therefore, brain mitochondrial dysfunction could be an important feature in AD patho-
genesis in the MetS condition. Furthermore, the elevation of oxidative stress caused the imbal-
ance of brain mitochondrial dynamics [25]. Mitochondrial dynamics are a key process for the 
maintenance of cell life and death through the balancing of mitochondrial fission and fusion 
[26]. In the physiological status of the brain, mitochondrial dynamics enables mitochondria 
to recruit subcellular components, exchange substrates between mitochondria, and control 
mitochondrial shape [26]. Recently, it has been proposed that brain mitochondrial dynamic 
imbalance is another mechanism that is involved in the brain pathogenesis of MetS and AD 
[27, 28]. Examples from the recent research are as follows: (1) several studies have reported 
that levels of Dynamin-related protein 1 (Drp1) and mitochondrial fission 1 (Fis1), markers 
of mitochondrial fission, were increased in the brains of MetS and AD animals [29, 30], lead-
ing to neuronal apoptosis [29]; (2) mitochondrial fusion protein levels were decreased in the 
brains of both MetS and AD animals [29, 30]. Therefore, a mitochondrial dynamic imbalance 
may play an important role in cognitive dysfunction in MetS and AD [26, 30]
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2. The implications of metabolic syndrome on brain mitochondria 
and its association with the development of AD: in vivo studies and 
clinical studies
2.1. MetS condition from a high-fat diet-induced obese-insulin-resistant model
Obese-insulin resistance is characterized by body weight gain and peripheral insulin insen-
sitivity [20–22, 31–34]. These characteristics are similar to those seen in the MetS condition in 
humans. In addition to peripheral insulin resistance, brain insulin resistance has also been 
reported in the obese condition in rats [20–22, 31, 34]. A diet containing 60% E from fat is consid-
ered to be a high-fat diet (HFD), and it has been widely used to induce obese-insulin resistance 
in rodents [20–22, 31–33]. In some studies, it has been found that HFD consumption increased 
plasma cholesterol and free fatty acid levels [20–22, 31, 32, 34]. However, the plasma glucose 
level was not increased, but hyperinsulinemia was observed following HFD consumption even 
after long-term consumption of a HFD (12 months), indicating a pre-diabetic state [20, 31–34].
HFD consumption between 16 weeks and 12 months caused brain mitochondrial damage, 
including an increased mitochondrial ROS production [20–22, 31, 34], a reduced mitochon-
drial membrane potential [19, 31, 34–36], and an impaired mitochondrial morphology as 
indicated by an increased mitochondrial swelling [20–22, 31, 33]. Furthermore, HFD reduced 
adenosine triphosphate (ATP) production [34]. Although several studies suggested that HFD 
caused brain mitochondrial dysfunction, Jorgensen et al. reported that HFD did not impair 
brain mitochondrial function even when the rats were given a HFD for 12 months. Therefore, 
the effects of a HFD on brain mitochondrial function still need to be elucidated.
There are several studies which have shown that brain mitochondrial damage could impair 
cognitive function and synaptic plasticity [20–22, 31, 33, 34]. Various cognitive tests have been 
used such as the Morris water maze (MWM), novel object recognition (NOR), novel object 
smelling (NOS), and Y-maze test. The MWM and Y-maze are tests for hippocampal-dependent 
learning process, including the acquisition of spatial memory and long-term spatial memory 
[36]. NOR and NOS are used to assess non-force driving and spontaneous memory [35, 37].
Rats and mice fed on a HFD for 16–20 weeks had an increased time to reach the platform and 
a decreased time in the target quadrant and crossing target number, compared with normal 
diet (ND)-fed animals, when cognitive function was assessed using the MWM [20–22, 31, 34]. 
Furthermore, recognition index was decreased in HFD-fed mice, compared to ND-fed mice 
[34]. Mice fed on a HFD for 12 months did not indicate an impaired discrimination index fol-
lowing the NOS test, but there were decreased percentage correction alterations in the Y-maze 
test [33]. These accumulative data suggested that the consumption of a HFD caused obese-insu-
lin resistance, brain mitochondrial dysfunction, and synaptic dysplasticity, possibly leading to 
cognitive dysfunction. However, no study has demonstrated brain mitochondrial dysfunction 
with elevated AD markers such as Aβ levels and hyperphosphorylated tau in HFD-fed animals. 
This suggests that obese-insulin resistance can lead to the development of brain mitochondrial 
dysfunction and cognitive impairment or MCI or pre-AD without AD symptoms. Data regard-
ing the effects of HFD-induced obese-insulin resistance on brain mitochondria and its associa-
tion with the development of AD are shown in Table 1 and are summarized in Figure 1.
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Study model Major findings Refs
Animal/diet/duration Metabolic parameters Mitochondrial 
parameters
Cognitive function AD 
marker
Interpretation
Wistar rats/HFD (60% 
E fat) or ND (20% E 
fat)/16 weeks
• ↑ BW, insulin, HOMA, 
cholesterol
• ↔Glucose
• ↓Peripheral insulin 
sensitivity
• ↓Brain insulin signaling
• ↑ ROS
• ↓ MMP
 ○ ↑Swelling
MWM
• ↑Time to reach platform
• ↓Time in target quadrant
Synaptic plasticity
• ↓LTP
N/A HFD-induced obese-insulin 
resistance leads to synaptic 
dysplasticity and brain 
mitochondrial dysfunction and 
finally results in cognitive decline.
[20–22, 
31]
C57BL/6 mice/HFD or 
ND/20 weeks
• ↑BW, insulin, HOMA, 
FA, cholesterol
• ↓Peripheral insulin 
sensitivity
• ↓Brain insulin signaling
• ↑ROS
• ↓MMP
• ↓ATP
NOR
• ↓Recognition index
MWM
• ↓Time in target quadrant
• ↓Crossing target number
N/A HFD-induced obese-insulin 
resistance leads to brain 
mitochondrial dysfunction and 
cognitive dysfunction.
[34]
C57BL/6 mice/HFD (60% 
E fat) or ND (12% E 
fat)/12 months
• ↑ BW, insulin
• ↔Glucose
• ↑Swelling 
(elongated 
mitochondria)
NOS
• ↔Discrimination index
Y-maze test
• ↓% Correct alterations
Synaptic plasticity
• ↓Synaptic density
N/A HFD-induced obese-insulin 
resistance leads to synaptic 
dysplasticity, brain mitochondrial 
dysfunction and cognitive 
dysfunction.
[47]
Wistar rats/HFD (60% 
E fat) or ND (13% E 
fat)/12 months
• ↑BW, insulin, HOMA, 
FA
• ↔Glucose
• ↔ State 3, 4 
respiration
• ↔ RCR
N/A N/A HFD-induced obese-insulin 
resistance does not impair brain 
mitochondrial function.
[32]
Abbreviations: BW, body weight; HOMA, homeostasis model assessment; HFD, high-fat diet; ND, normal diet; ROS, reactive oxygen species; MMP, mitochondrial 
membrane potential; RCR, respiratory control ratio; MWM, Morris water maze; LTP, long-term potentiation; NOR, novel object recognition; NOS, novel smell recognition; 
N/A, not assessed.
Table 1. Implications of obese-insulin resistance on brain mitochondria and its association with the development of Alzheimer’s disease.
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2.2. Type 2 diabetes mellitus model
Type 2 diabetes mellitus (T2DM) is diagnosed when hyperglycemia is observed along with 
insulin resistance [38–41]. In order to create a T2DM animal model, a combination of a HFD 
with low-dose streptozotocin, and a high-calorie diet were used [38–41]. Both regimens 
caused hyperglycemia in rodents [38–41]. Similar to obese-insulin-resistant models, T2DM 
animals are also found to develop brain mitochondrial damage [38–41].
Beside the effects of T2DM on oxidative stress and mitochondrial membrane depolarization, 
nuclear respiratory factor 2 (NRF2) levels were reduced in the brains of T2DM mice [38]. 
NRF2 acts as an antioxidant and detoxifying enzyme and helps to reduce oxidative stress in 
mitochondria [42]. Therefore, a decreased level of NRF2 directly impairs the brain mitochon-
drial redox system, which leads to the reduction of brain mitochondrial antioxidant capacity. 
In addition, a previous study showed a decrease in brain mitochondrial numbers in T2DM 
mice [41]. The possible explanation may be due to a decrease in NRF2 in the brain of T2DM 
mice, in which NRF2 regulates brain mitochondrial biogenesis [43]. These data indicate that 
T2DM caused brain mitochondrial damage and brain mitochondrial dysfunction, resulting in 
an increased brain oxidative stress.
Consistent with the findings from obese-insulin-resistant animals, T2DM animals also devel-
oped brain mitochondrial dysfunction with cognitive impairment, quantified using the 
MWM test, as indicated by an increased escape latency and time in target quadrant and a 
decreased crossing target number [39, 41]. Also, T2DM rats had decreased percentage cor-
rection alterations and total distance, when the abilities of these animals were investigated 
using the Y-maze test [39]. T2DM also affected brain synaptic plasticity proteins, as indicated 
by reducing postsynaptic density protein 95 (PSD95) and synaptosomal-associated protein 25 
(SNAP25) levels [38]. However, T2DM did not affect synaptophysin protein levels [38].
Figure 1. The effects of insulin resistance and T2DM on brain mitochondria and their association with the development 
of Alzheimer’s disease in non-AD and AD models.
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In the T2DM model, brain mitochondrial markers were evaluated along with the changes in 
AD markers. It is interesting that T2DM rats developed AD signs, specifically that the levels 
of AD markers, including Aβ42 and hyperphosphorylated tau, were significantly increased in 
T2DM rats, when compared with non-T2DM rats [39, 41]. In addition, acetylcholine esterase 
enzyme activity was increased, and ACh levels were decreased in the brains of T2DM mice 
[39]. These data suggested that T2DM rats had impaired brain mitochondrial dysfunction 
and synaptic plasticity, leading to cognitive dysfunction and showed increased AD mark-
ers. Interestingly, those findings indicated that AD was developing in the T2DM condition. 
Contrary to the findings from animal studies, when Loo et al. investigated the effect of T2DM 
on mitochondrial function in human mononuclear cells, their data showed that T2DM did 
Study model Major findings Refs
Animal/diet/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive function AD 
marker
Interpretation
SD rats/HFD 
(60% E fat) + STZ 
(30 mg/kg, i.p.) 
or ND + citrate 
buffer/11 weeks
• ↑BW, insu-
lin, glucose
• ↓Peripheral 
insulin 
sensitivity
• ↓Brain 
insulin 
signaling
• ↓Mito 
number
• ↑ROS
• ↓MMP
MWM
• ↑Escape latency
• ↓Crossing target 
number
• ↑Aβ42 T2DM causes brain 
mitochondrial 
dysfunction, 
increases levels 
of AD markers, 
and cognitive 
dysfunction.
[41]
C57BL/6 mice/
HFD (60% E fat) 
or ND (10% E 
fat)/10 weeks
• ↑Glucose • ↑ROS
• ↓MMP
• ↓ATP
MWM
• ↑Escape latency
• ↓Time in target 
quadrant
Y-maze test
• ↓% Correct 
alterations
• ↓Total distance
• ↑pTau/
Tau
• ↑AChE 
activity
• ↓ACh
T2DM causes brain 
mitochondrial 
dysfunction, 
increases levels 
of AD marker, 
and cognitive 
dysfunction.
[39]
Wild-type mice/
sucrose(20%) 
solution or control
(water)/7 months
• ↑BW, insu-
lin, HbA1c
• ↓RCR
• ↓MMP
• ↓ATP
• ↓NRF2
Synaptic plasticity
• ↓PSD95
SNAP25
• ↔Synaptophysin
N/A T2DM causes 
mitochondrial 
dysfunction and 
impairs synaptic 
plasticity.
[38]
T2DM patients 
compared to 
healthy controls
N/A • ↔ROS
• ↔MMP
• ↔ATP
N/A N/A T2DM is not 
associated with 
mitochondrial 
dysfunction.
[40]
Abbreviations: BW, body weight; STZ, streptozotocin; T2DM, type 2 diabetes mellitus; HFD, high-fat diet; ND, normal 
diet; ROS, reactive oxygen species; MMP, mitochondrial membrane potential; Ach, acetylcholine; AChE, acetylcholine 
esterase; ATP, adenosine triphosphate; RCR, respiratory control ratio; NRF, nuclear respiratory factor; MWM, Morris 
water maze; N/A, not assessed.
Table 2. Implications of type 2 diabetes mellitus (T2DM) on brain mitochondria and its association with the development 
of Alzheimer’s disease.
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not affect mitochondrial function [40]. Their findings showed that T2DM affected regional 
mitochondria, but not systemic mitochondria. Data regarding the effects of T2DM on brain 
mitochondria and its association with the development of AD are shown in Table 2 and are 
summarized in Figure 1.
3. The implications of high-calorie diet consumption on brain 
mitochondrial function and brain function in an AD model: in vivo 
studies
Two AD animal models, including 3xTg AD mice and APPswe/PS1dE9 mice, have been used to 
investigate the implications of high-calorie diet consumption on brain mitochondrial function 
Study model Major findings Refs
Animal/diet/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive function AD marker Interpretation
3xTgAD 
mice/HFD 
(60% E fat) or 
ND (12% E 
fat)/12 months
- ↑ BW
- ↔ Glucose, 
insulin
• ↔Mito 
number
• ↔Mito 
morphology
NOR
• ↔Discrimination 
index
Y-maze test
• ↔ % Correct 
alterations
Synaptic plasticity
• ↔ Synaptic 
number
• ↔Aβ42 Obesity did not alter 
brain mitochondria 
and AD markers AD 
model.
[33]
APPswe/PS1 
dE9 mice/HFD 
(45% E fat) or 
ND/12 weeks
• ↑BW
• ↔Brain 
insulin 
signaling
• ↓PGC1α
• ↔NRF1,2
• TFAM
N/A • ↑APP
• ↓ADAM10
• ↓IDE
• ↔BACE1
• ↑Cortical 
soluble 
Aβ40, 
Aβ42 
insoluble 
Aβ42
Obesity increased 
AD markers, but 
did not alter brain 
mitochondrial 
biogenesis in AD 
model.
[17]
APPswe/PS1 
dE9 mice/HFD 
(45% E fat) or 
ND/24 weeks
• ↑BW, 
insulin, 
glucose
• ↓Peripheral 
insulin 
sensitivity
• ↓Brain 
insulin 
signaling
• ↓PGC-1α
• ↓NRF1,2
NOR
• ↓Discrimination 
index
• ↔APP
p-Tau/Tau
• ↓IDE
• ↑Cortical 
insoluble 
Aβ42
Obesity increased 
AD markers, 
impaired brain 
mitochondria 
biogenesis, and 
cognitive function in 
AD model.
[18]
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and brain function. 3xTg AD mice cells with the mutations Thy-1.2-driven APP-Swedish and tau 
P301L were co-injected into a homozygous PS1M146V knock-in background. This type of AD 
mice had parenchymal plaque by 6 months of age combined with tau pathology by 12 months 
of age [44]. In APPswe/PS1dE9 mice, APP/PS1 animals co-express a Swedish (K594 M/N595 L) 
mutation of a chimeric mouse/human APP (Mo/HuAPP695swe), together with the human exon-
9-deleted variant of PS1 (PS1-dE9), which leads to an increase in human Aβ peptide secretion in 
the brain of APPswe/PS1dE9 mice [17, 18].
There is only one study that has compared the brain mitochondrial function between T2DM 
and AD animal models. The investigators reported that both T2DM and AD mice had similar 
degrees of brain mitochondrial dysfunction, decreased synaptic plasticity proteins levels, and 
raised AD markers [38]. Those findings indicated that AD pathology was developed in T2DM 
animals, with an involvement of brain mitochondrial dysfunction.
The provision of a HFD to AD mice resulted in a different outcome depending on a genetic 
background of the AD mice. In 3xTg AD mice, the provision of a HFD led to increased body 
weight, but did not alter plasma glucose and insulin levels, compared to 3xTg AD mice given 
an ND [33]. In addition, the brain mitochondrial number and brain mitochondrial morphol-
ogy, as well as cognitive function and AD markers were not affected by the HFD [33]. The data 
from this study suggested that T2DM did not alter brain mitochondria, cognitive function, 
or AD markers in 3xTgAD mice. By contrast, the consumption of a HFD led to a markedly 
decreased brain mitochondrial biogenesis and aggravated cognitive impairment in APPswe/
PS1dE9 mice [17, 18]. Furthermore, a HFD aggravated AD pathogenesis in APPswe/PS1dE9 
mice, as indicated by increased cortical soluble and insoluble Aβ, and decreased insulin-
degrading enzymes [17, 18]. Data regarding the effects of consumption of a high-calorie diet 
on brain mitochondrial function and brain function in the AD model are shown in Table 3 and 
are summarized in Figure 1.
Study model Major findings Refs
Animal/diet/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive function AD marker Interpretation
Sucrose (20% 
sucrose) 
fed mice or 
3xTgAD mice 
fed with ND
N/A • ↔RCR
• ↔MMP
• ↔ATP
• ↔NRF2
Synaptic plasticity
• ↔PSD95, 
synaptophysin, 
SNAP25
N/A T2DM and AD 
mice exhibited 
similar phenotypes 
as regards brain 
synaptic plasticity 
and brain 
mitochondrial 
function.
[38]
Abbreviations: AD, Alzheimer’s disease; HFD, high-fat diet; ND, normal diet; BW, body weight; PGC, peroxisome 
proliferator-activated receptor gamma; NRF, nuclear respiratory factor; TFAM, mitochondrial transcription factor 
A; RCR, respiratory control ratio; MMP, mitochondrial membrane potential; ATP, adenosine triphosphate; PSD, 
postsynaptic density protein; SNAP, synaptosomal-associated protein; NOR, novel object recognition; N/A, not assessed.
Table 3. Implications of high-calorie diet consumption on brain mitochondria and brain function in an Alzheimer’s 
disease model.
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4. Therapeutic approaches on rats with the MetS condition specific 
to brain mitochondrial dysfunction and its association with the 
development of AD
Several studies have used various interventions on brain mitochondria and described their 
associations with the development of pre-AD. In this report, we have separated these interven-
tions into three categories: (1) antidiabetic drugs, (2) traditional medicine, and (3) other drugs.
4.1. Antidiabetic drugs
Several studies have demonstrated the beneficial effects of antidiabetic drugs on insulin sensi-
tivity and brain mitochondrial function [21, 31, 45]. Our previous study found that the sodium 
glucose cotransporter 2 (SGLT2) inhibitor, which is a new antidiabetic drug, could decrease 
metabolic disturbance, brain mitochondrial ROS production, brain mitochondrial membrane 
potential change, brain mitochondrial swelling, synaptic dysplasticity and cognitive decline 
in HFD-fed rats [21]. In addition, the incretin-based drugs such as sitagliptin and vildagliptin, 
dipeptidyl peptidase-4 (DPP-4) inhibitors, also had beneficial effects on the improvement of 
insulin sensitivity, brain mitochondrial function and cognitive function in HFD-fed rats [21, 
31, 45]. Another incretin-based drug, liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, 
also improved insulin sensitivity and decreased brain mitochondrial swelling [45]. All of 
these findings indicated that the antidiabetic drugs could reduce peripheral and brain insulin 
resistance, leading to improvement in cognitive function and synaptic plasticity and were 
associated with improved brain mitochondrial function. However, there is still lack of evi-
dence showing the effects of antidiabetic drugs on AD markers. Data pertinent to the effect of 
antidiabetic drugs on brain mitochondrial dysfunction and their association with the devel-
opment of pre-AD in the MetS condition are shown in Table 4.
4.2. Traditional medicine
Several studies have shown the beneficial effects of traditional medicine on brain mito-
chondrial function in HFD-fed, T2DM and AD rat models [20, 34, 39, 41]. Naringin, a citrus 
flavonoid, can improve insulin sensitivity and decrease brain mitochondrial ROS produc-
tion, brain mitochondrial membrane potential change, brain mitochondrial ATP produc-
tion, and cognitive decline in HFD-fed mice [34]. Furthermore, our previous studies found 
that garlic extract reduced peripheral and brain insulin resistance, brain mitochondrial 
ROS production, brain mitochondrial membrane potential change, and brain mitochon-
drial swelling, leading to improved cognitive function in HFD-fed rats [20]. The ZiBuPiYin 
recipe (ZBPYR), a traditional Chinese medicine, reduced brain mitochondrial ROS pro-
duction, increased brain mitochondrial membrane potential change, increased brain mito-
chondrial number, and decreased cortical insoluble Aβ42, leading to improved cognitive 
function in T2DM mice [41]. Dendropanax morbifera (Araliaceae), a herbal medicine in Asia, 
improved peripheral and brain insulin sensitivity, decreased brain mitochondrial ROS 
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production, increased brain mitochondrial membrane potential change, and increased 
brain mitochondrial ATP production, leading to a decrease in cognitive decline in HFD-fed 
mice [39]. All of these traditional medicines contain flavonoid and phenolic compounds 
which have antioxidant properties, and it is thought that these properties may play an 
important role in the improvement of insulin sensitivity and brain mitochondrial function, 
leading to improved cognitive function. Data regarding the effect of traditional medicine 
on brain mitochondrial dysfunction and its association with a delay in the development of 
pre-AD in association with MetS are shown in Table 5.
Study model Major findings Refs
Animal/
interventions/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive 
function
AD 
marker
Interpretation
HFD-fed rats/
SGLT2 inhibitor 
(1 mg/kg) or 
vehicle/4 weeks
• ↓BW
• ↑Peripheral 
insulin 
sensitivity
• ↑Brain 
insulin 
signaling
• ↓ROS
• ↑MMP
• ↓Swelling
MWM
• ↓Time 
to reach 
platform
• ↑Time 
in target 
quadrant
Synaptic 
plasticity
• ↑LTP
N/A SGLT2 inhibitor reduced 
peripheral and brain insulin 
resistance, improved brain 
mitochondrial function, and 
improved cognitive function 
and synaptic plasticity in 
obese-insulin-resistant rats.
[21]
HFD-fed rats/
vildagliptin 
(3 mg/kg) or 
vehicle/3 weeks
• ↔ BW
• ↓Insulin 
HOMA
• ↓ROS
• ↑MMP
• ↓Swelling
MWM
• ↓Time 
to reach 
platform
• ↑Time 
in target 
quadrant
N/A DPP-4 inhibitor reduced 
peripheral and brain insulin 
resistance, improved brain 
mitochondrial function, and 
improved cognitive function 
in obese-insulin-resistant rats.
[31]
HFD-fed rats/
sitagliptin 
(30 mg/kg) or 
vehicle/3–4 weeks
• ↔ BW
• ↓Insulin 
HOMA
• ↓ROS
• ↑MMP
• ↓Swelling
MWM
- ↓ Time 
to reach 
platform
- ↑ Time 
in target 
quadrant
N/A DPP-4 inhibitor reduced 
peripheral and brain insulin 
resistance, improved brain 
mitochondrial function, and 
improved cognitive function 
in obese-insulin-resistant rats.
[31, 45]
HFD-fed rats/
liraglutide 
(0.6 mg/kg) or 
vehicle/3 weeks
• ↔ BW
• ↓Peripheral 
insulin 
sensitivity
• ↓Swelling N/A N/A Liraglutide reduced 
peripheral resistance 
and improved brain 
mitochondrial function in 
obese-insulin-resistant rats.
[45]
Abbreviations: HFD, high-fat diet; ND, normal diet; DPP-4, dipeptidyl peptidase 4; SGLT2, sodium glucose transporter 
2; BW, body weight; ROS, reactive oxygen species; MMP, mitochondrial membrane potential; MWM, Morris water 
maze; NA, not assessed.
Table 4. Potential effects of antidiabetic drugs on brain mitochondria and their association with the development of 
Alzheimer’s disease.
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Study model Major findings Refs
Animal/
interventions/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive 
function
AD marker Interpretation
HFD-fed rats/
naringin 
(100 mg/kg) or 
vehicle/20 weeks
• ↓BW
• ↑Peripheral 
insulin 
sensitivity
• ↑ Brain insulin 
signaling
• ↓ROS
• ↑MMP
• ↑ATP
NOR
• ↑Recognition 
index
MWM
• ↑Time in tar-
get quadrant
• ↑Crossing 
target number
N/A Naringin reduced 
peripheral and 
brain insulin 
resistance, 
improved brain 
mitochondrial 
function, and 
improved cognitive 
function in obese-
insulin-resistant 
rats.
[34]
HFD-fed 
rats/garlic 
extract (200, 
500 mg/kg) or 
vehicle/3 weeks
- ↔ BW
• ↑Peripheral 
insulin 
sensitivity
• ↑ Brain insulin 
signaling
• ↓ROS
• ↑MMP
• ↓Swelling
MWM
• ↓Time to 
reach platform
• ↑Time in tar-
get quadrant
N/A Garlic extract 
reduced peripheral 
and brain insulin 
resistance, 
improved brain 
mitochondrial 
function, and 
improved cognitive 
function in obese-
insulin-resistant 
rats.
[20]
HFD-fed 
rats/Dendropanax 
morbifera (20 and 
50 mg/kg) or 
vehicle/10 weeks
• ↑Peripheral 
insulin 
sensitivity
• ↓ROS
• ↑MMP
• ↑ATP
MWM
• ↑Time in tar-
get quadrant
Y-maze
• ↑Alternation 
behavior
• ↑Total 
distance
N/A Dendropanax 
morbifera reduced 
peripheral and 
brain insulin 
resistance, 
improved brain 
mitochondrial 
function, and 
improved cognitive 
function in obese-
insulin-resistant 
rats.
[41]
HFD-fed mice 
+ low-dose 
STZ/Chinese 
medicine ZiBu 
PiYin recipe or 
vehicle
• ↔ BW
• Peripheral 
insulin 
sensitivity
• ↓ROS
• ↑MMP
• ↑Mito 
number
MWM
• ↑Time in tar-
get quadrant
• ↑Crossing 
target number
• ↓Cortical 
insoluble 
Aβ42
Although Chinese 
medicine did not 
improve peripheral 
insulin resistance, 
it improved brain 
mitochondrial 
function, improved 
cognitive function, 
and reduced AD 
marker in T2DM 
rats.
[39]
Abbreviations: HFD, high-fat diet; ND, normal diet; BW, body weight; ROS, reactive oxygen species; MMP, mitochondrial 
membrane potential; NOR, novel object recognition; MWM, Morris water maze; NA, not assessed.
Table 5. Potential effects of traditional medicine on brain mitochondria and its association with the development of 
Alzheimer’s disease.
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4.3. Other drugs
The other therapies such as fibroblast growth factor 21 (FGF21), hydroxytyrosol 2-(3,4-di-
hydroxyphenyl)-ethanol, and mitochondrial fission inhibitors also had beneficial effects on 
brain mitochondrial function in HFD-fed, T2DM and AD models. Our previous study found 
that an endocrine hormone, FGF21, decreased metabolic disturbance, brain mitochondrial 
ROS production, brain mitochondrial membrane potential change, brain mitochondrial 
swelling, synaptic dysplasticity, and cognitive decline in rats with MetS induced by the con-
sumption of a HFD [22]. Hydroxytyrosol 2-(3,4-di-hydroxyphenyl)-ethanol, a major anti-
oxidant phenol in olive oil, ameliorated mitochondrial dysfunction, reduced mitochondrial 
carbonyl protein, and enhanced superoxide dismutase 2 expression in AD mice. However, 
this drug did not affect Aβ accumulation in these AD mice [46]. The mitochondrial fission 
inhibitor, mdivi-1, improved synaptic plasticity and was associated with improving brain 
Study model Major findings Refs
Animal/interventions/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive 
function
AD 
marker
Interpretation
HFD-fed rats/FGF21 
(0.1 mg/kg) or 
vehicle/20 weeks
• ↓ BW
• ↑Peripheral 
insulin 
sensitivity
• ↑ Brain insulin 
signaling
• ↓ ROS
• ↑ MMP
• ↓ Swelling
MWM
• ↓ Time 
to reach 
platform
• ↑ Time 
in target 
quadrant
Synaptic 
plasticity
• ↑ LTP
N/A FGF21 reduced 
peripheral and 
brain insulin 
resistance, 
improved brain 
mitochondrial 
function and 
cognitive 
function in obese-
insulin-resistant 
rats.
[22]
APP/PS1 mice/
hydroxytyrosol 
(50 mg/kg) or 
vehicle/8 weeks
N/A • ↑OXPHOS 
I, IV
• ↑ PGC1-α
N/A ↔ Aβ 
levels
Hydroxytyrosol 
improved 
mitochondrial 
function and 
increased 
mitochondrial 
biogenesis in 
T2DM mice.
[46]
db/db mice/mdivi-1 
(50 mg/kg) or 
vehicle/2 weeks
N/A • ↑Mito density
• ↑OXPHOSI
• ↑ ATP
Synaptic 
plasticity
• ↑ LTP
N/A Mitochondrial 
fission inhibitor 
improved brain 
mitochondrial 
function and 
brain synaptic 
plasticity in 
T2DM mice.
[30]
Abbreviations: HFD, high-fat diet; ND, normal diet; BW, body weight; ROS, reactive oxygen species; MMP, mitochondrial 
membrane potential; OXPHOS, oxidative phosphorylation; PGC, peroxisome proliferator activated receptor gamma; 
ATP, adenosine triphosphate; LTP, long-term potentiation; N/A, not assessed.
Table 6. Potential interventions on brain mitochondria and their association with the development of Alzheimer’s disease.
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mitochondrial function and biogenesis via increasing mitochondrial density, OXPHOS I, and 
ATP production in T2DM mice [30]. All of these findings indicated that the SGLT2 inhibitor, 
vildagliptin, liraglutide, FGF21, naringin, garlic extract, and D. morbifera improved not only 
peripheral insulin sensitivity but also brain insulin sensitivity, brain mitochondrial function, 
and cognitive function. Hydroxytyrosol, Mdivi-1, and ZiBuPiYin improved brain mitochon-
drial function and cognitive function. However, only ZiBuPiYin reduced levels of AD mark-
ers, possibly resulting in improved cognitive function.
Data regarding the effect of other drugs on brain mitochondrial dysfunction and the associa-
tion of this dysfunction with the development of pre-AD in the MetS condition are shown in 
Table 6. The summarized therapeutic approaches on brain mitochondria and their association 
with the development of AD are shown in Figure 2.
In addition, previous studies showed that acetylcholine (Ach) levels of AD brain were lower 
than that of healthy brain [6, 12]. Therefore, acetylcholinesterase inhibitors (AChEs) are com-
monly used for the symptomatic treatment of AD patients. Previous in vivo study and clini-
cal study demonstrated that AChEIs have an effect on mitochondrial function (REFs). For 
example, (1) Donepezil (AChEI) attenuated brain mitochondrial dysfunction by reducing 
calcium-induced brain mitochondrial swelling and reduced mitochondrial Aβ40 and Aβ42 
accumulation in AD mice, leading to improved cognitive function in AD mice [47]. (2) A 
clinical study by Casademont et al. showed that rivastigmin, AChEI, enhanced mitochon-
drial electron transport chain function as indicated by increased complex I and complex III 
of mitochondrial oxidation and increased enzymatic activities of complexes II, III, and IV 
Figure 2. Summarized therapeutic approaches on brain mitochondria and their association with the development of 
Alzheimer’s disease. Abbreviations: SGLT2, sodium-glucose transporter 2; PI3K, phosphoinositide 3 kinase; Akt, protein 
kinase B; FGF 21, fibroblast growth factor 21.
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in the lymphocytes from AD patients [48]. (3) By contrast, tacrine, AChEI, impaired brain 
mitochondrial respiratory complex I, IV, and V activities in XX model [49]. Therefore, further 
studies are required to provide more evidence to support the effects of AChE inhibitor on 
brain mitochondrial function in AD patients as well as in the metabolic syndrome subjects. 
Those findings of AChEIs on brain mitochondrial function and their association with the 
development of Alzheimer’s disease are summarized in Table 7.
5. Clinical implications
The presence of MetS is associated with an increase in the incidence of pre-AD. The possible 
underlying mechanisms involved in the association of pre-AD in MetS are still unclear. From 
this study, we concluded that mitochondrial dysfunction could be an important feature of AD 
pathogenesis in MetS. In addition, the findings indicate that the intervention which improved 
brain mitochondrial function led to improved cognitive function. These findings provide 
Study model Major findings Refs
Models/
interventions/
duration
Metabolic 
parameters
Mitochondrial 
parameters
Cognitive function AD 
marker
Interpretation
APP/PS1 (APPswe/
PS1dE9)/Donepezil (1 
mg/kg) or vehicle/2 
months
N/A • ↓Ca2+ induced 
mitochondrial 
swelling
T maze
• ↑%Accuracy
Elevated plus maze
• ↑Entry number 
into open arm
• ↑Time in open 
arm
- ↓ Mito Aβ 
40,42
Donepezil 
attenuated 
brain 
mitochondrial 
swelling, 
reduced 
brain Aβ 
accumulation, 
and improved 
cognitive 
function in AD 
mice.
[47]
AD patients/
rivastigmin (6–12 mg/
day)/6 months
N/A • ↑Oxidation of 
complex I and III
• ↑Enzymatic activi-
ties of complex II, 
III and IV
• ↔Mitochondrial 
content
N/A N/A Rivastigmin 
enhanced 
mitochondrial 
electron 
transport chain 
function in AD 
patients.
[48]
Wistar rats/tacrine (15 
mg/kg)/8 h
N/A • ↓ Complex I, IV, V 
activity
N/A • ↓AChE Tacrine 
impaired brain 
mitochondrial 
function in 
rats.
[49]
Abbreviations: AChE, acetylcholinesterase; APP, amyloid beta precursor; AD, Alzheimer’s disease; Ca2+, calcium; Aβ, 
amyloid beta; N/A, not assessed.
Table 7. The effects of acetylcholine esterase inhibitors (AChEIs), the standard drugs for AD treatment, on brain 
mitochondrial function and their association with the development of Alzheimer’s disease.
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information regarding the role of mitochondria in the underlying mechanisms of pre-AD in 
MetS and offer important insights for future research on interventions that aim to improve the 
quality of life in MetS patients with AD.
6. Conclusion
In this study, the accumulated data led to the conclusion that although cognitive decline and 
brain mitochondrial dysfunction were observed in obese-insulin-resistant rats, AD was not 
developed during the pre-diabetic state. In addition, markers indicating the presence of AD 
were observed in T2DM subjects. Treatment with antidiabetic drugs, traditional medicine, 
FGF21, and mitochondrial fission inhibitors effectively improved brain mitochondrial func-
tion and cognitive function in rats with induced MetS.
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